Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...
Conclusions In asymptomatic persons at average risk for colorectal cancer, multitarget stool DNA testing detected significantly more cancers than did FIT but had more false positive results. (Funded ...
Increased sensitivity of test that detects the second deadliest cancer will save hundreds of lives, oncologists say ...
Annual fecal immunochemical test-based surveillance could be as effective as colonoscopies in reducing long-term colorectal cancer incidence and mortality, according to a recent study published in ...
More than 10% of fecal immunochemical test (FIT)–based colorectal cancer screening could not be processed due to unsatisfactory samples. Colorectal cancer (CRC) screening using the fecal ...
By reducing the level at which traces of blood in a FIT test trigger further investigation – from 120 micrograms of blood per gram of poo down to 80 – the NHS will offer 35% more screening ...
VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...
Re-analysis of US Preventive Services Task Force colorectal cancer screening guidelines shows that every-3-year screening with multi-target sDNA could address poor performance of recommended annual ...
Colorectal cancer (CRC) is a leading cause of death among men and women in the USA. Encouragingly, the reported death rates from CRC in the USA have dropped by 46%, and screening has had an important ...
Major change to bowel cancer screening as thousands more to be tested - The NHS aims to detect thousands more bowel cancer ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results